← All health signals
Governance

Medicine of One

Treatment can be matched to one patient’s genome, not the trial average: the FDA clears blood tests that match patients to drugs and drafts a path for bespoke rare-disease therapies.

What is it?

A cancer diagnostic can now be approved around one patient’s blood draw, not a biopsy, with AI trained on a million patients behind it, and sequencing keeps getting cheaper. What’s missing is the plumbing between a genomic result and the prescription written on it.

Why now?

Sequencing costs dropped as diagnostics moved from a research tool toward a routine step, and regulators started approving tests built around a single patient’s biology rather than a population average. The limiter isn’t the science anymore — it’s reimbursement and clinical workflow.

Who’s building it?

Diagnostics makers and sequencing platforms are building the test; prescribers and payers still decide whether it counts.

Diagnostics makersSequencing platformsRegulators · FDAPrescribersPayers
The full read
Why now, who is building it, where the market goes, and what stays unsettled.
Get weekly →
01 · The market
Who’s in it
Builders — diagnostics companies, and the sequencing platforms beneath them.
Buyers — prescribers and payers deciding whether a genomic result changes a treatment plan.
Gatekeepers — regulators approving each companion diagnostic, one indication at a time.
What’s at stake
The value sits less in sequencing than in whoever wires a result into the prescribing moment — integration is the prize.
Reimbursement lag turns a capable test into an unused one.
Each approval covers one indication, not medicine generally.
What’s unsettled
Whether payers reimburse fast enough to make routine testing the norm.
Whether workflow integration, not sequencing, becomes the real bottleneck.
Whether one-patient-at-a-time approval scales into a norm, or stays a slow, case-by-case grind.
02 · How the demand matureda progression, not a timeline
Approval
Regulators sign off on tests built around narrow genetic subgroups.
Workflow
A blood-based result has to reach the prescriber before the decision is made.
Reimbursement
Payers decide whether routine genomic testing ahead of prescribing gets covered like any other diagnostic step.
Standard of care
Enough covered, integrated cases and testing stops being optional.
03 · Where the market goesthe forks, not a prediction
→Converge or fragment — one integration layer serving every diagnostic and drug, or a separate wiring job for each disease area.
→Payers could standardise reimbursement quickly, or leave genomic testing a slow, indication-by-indication approval fight.
→Sequencing platforms could capture the value themselves, or cede it to whoever owns the workflow layer.
→Case-by-case approval could scale into a norm, or stay a narrow, costly exception.
The open question is whether the plumbing between a genomic result and a prescription gets built fast enough — before the decision is already made.
04 · The Bespoke Default deskadjacent markets, moving now
Generative Medicine
AI now designs the drug itself
AI-designed drug rentosertib entered Phase 3 trials.
ClinicalTrials.gov
The Always-On Tutor
Personalised instruction now scales well past the classroom
AI tutoring lifted scores 1.5-2 school years in 6 weeks.
World Bank
Hyper-Personal Media
Every ad now targets an audience of one
4M+ advertisers used Meta’s generative AI ad tools.
Marketing Dive
05 · The Wire
01
A blood draw, not a biopsy.
CURE ↗
02
Faster, cheaper sequencing.
Clinical Lab Products ↗
03
FDA approves Guardant360 Liquid CDx; Guardant says results come in 7 days
CancerNetwork ↗
04
FDA drafts an approval path for bespoke gene-editing therapies
Healio ↗
The panel on this signal
They agreed on
–Sequencing and diagnostics are no longer the constraint — workflow and reimbursement decide whether this reaches patients.
–Each approval covers one narrow indication, not disease broadly.
–Value is concentrating in the integration layer, not the sequencing hardware itself.
The clinical specialist disagreed on
–Current approvals proceed indication by indication under existing trial frameworks; a broader shift to standard clinical practice would require regulatory pathways built specifically for genome-matched treatment, which has not yet replaced the population-level approval process.
Know more about the method →
✦How this signal was built
01 · Panel
A Delphi panel of 4 AI analysts, each reasoning independently.
→
02 · Debate
They challenge and revise each other’s reads over two rounds.
→
03 · Evidence
Every claim is tied to a cited, linked source on The Wire.
→
04 · Synthesis
A moderator writes it into one read, disagreement and all.